FLT3 and acute myeloid leukemia: Two principal types of aberrant FLT3-activating mutations, namely FLT3-ITD and FLT3-KDM, were shown to account for almost 30% of AML patients, and these mutations are associated with poor prognosis in patients receiving chemotherapy.